CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients (VIEWER)
Actively Recruiting
About This Study
This pragmatic, multicenter randomized controlled trial evaluates the efficacy of the VIEWER virtual care platform in patients with advanced CKD (Stage 5) or ESRD. The intervention integrates a mobile tablet application with wireless devices to monitor BP, weight, oxygen saturation, and step counts, alongside weekly ESAS-r symptom surveys. These data are transmitted to a provider portal where clinicians receive flags for out-of-range values to inform multidisciplinary care and volume management. The study's primary objective is to determine if this semi-continuous telemonitoring reduces the composite of ED visits and hospitalizations compared to usual care during the high-risk transition toward dialysis. Secondary outcomes include all-cause mortality, acute inpatient dialysis initiation, and patient-reported quality of life assessed by KDQOL-SF and PREM scores.
Who Can Participate?
✓ Inclusion Criteria
- •>18 years of age
- •Patient or primary caregiver can read and speak English
- •Patient or patients substitute decision maker is able to provide informed consent
- •Patient or primary care giver cognitively and physically capable and willing to use the VIEWER mobile application and perform self-measurements (i.e. weight, BP, etc.)
- •Have stage 5 CKD (2 measurements of eGFR <15ml/min/1.73m2); eGFR will be calculated with the CKD-EPI equation, or have >40% chance of beginning dialysis in the next 2 years based on the Kidney Failure Risk Equation
- •Followed in a multidisciplinary CKD clinic
✗ Exclusion Criteria
- •Inability of self or caregiver assisted self-monitoring using VIEWER